Medicare Enrolled

Dr. Shari Flowers, M.D.

Rheumatology · Rockaway, NJ
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
66 E MAIN ST STE 2, Rockaway, NJ 07866
9738957676
In practice since 2008 (18 years)
NPI: 1902067937 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Flowers from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Flowers? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Flowers

Dr. Shari Flowers is a rheumatology specialist in Rockaway, NJ, with 18 years of NPI registration. Based on federal Medicare data, Dr. Flowers performed 46,277 Medicare services across 577 unique beneficiaries.

Between the years covered by Open Payments, Dr. Flowers received a total of $548 from 15 pharmaceutical and/or device companies across 34 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Flowers is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 18 years in practice ▲ Top 23% volume in NJ $548 industry payments

Medicare Practice Summary

Medicare Utilization ↗
46,277
Medicare services
Top 23% in NJ for rheumatology
577
Unique beneficiaries
$6
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~2,571 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Certolizumab injection (Cimzia)
An injection of certolizumab pegol administered under the direct supervision of a physician.
43,000 $4 $28
Denosumab injection (Prolia/Xgeva) 1,980 $19 $65
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
526 $98 $321
Non-hormonal chemotherapy injection
This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue.
247 $63 $302
Injection, methylprednisolone acetate, 40 mg 127 $6 $23
Joint injection, major joint
Removal of fluid from a large joint and/or injection of medication into the joint space.
125 $62 $293
Zoledronic acid injection, 1 mg
An injection of zoledronic acid administered at a dose of 1 mg.
70 $6 $399
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
50 $118 $537
Methylprednisolone acetate injection, 20 mg
A 20 mg injection of methylprednisolone acetate, a corticosteroid medication. This code specifies the drug and dosage administered.
43 $4 $14
New patient office visit, complex (60-74 min) 42 $186 $610
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
42 $74 $218
Joint fluid aspiration or injection, small joint
Removal of fluid from a small joint or injection of medication into a small joint.
25 $41 $197
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.1% high complexity
98.6% medium
1.3% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$548
Total received (2018-2024)
Avg $78/year across 7 years
Bottom 30% in NJ for rheumatology
15
Companies
34
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$533 (97.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$14 (2.6%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$146
2023
$50
2022
$68
2021
$14
2020
$12
2019
$106
2018
$152

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$92
Grifols USA, LLC
$22
AstraZeneca Pharmaceuticals LP
$18
Novartis Pharmaceuticals Corporation
$14
Top 3 companies account for 90.3% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$169
PFIZER INC.
$80
ABBVIE INC.
$52
Horizon Therapeutics plc
$51
Boehringer Ingelheim Pharmaceuticals, Inc.
$27
GlaxoSmithKline, LLC.
$24
Grifols USA, LLC
$22
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$21
AstraZeneca Pharmaceuticals LP
$18
Lundbeck LLC
$17
Novo Nordisk Inc
$15
Novartis Pharmaceuticals Corporation
$14
Genentech USA, Inc.
$14
Takeda Pharmaceuticals U.S.A., Inc.
$12
Lilly USA, LLC
$12
Top 3 companies account for 55.0% of all-time payments
Associated products mentioned in payments ›
Actemra · Aimovig · BREO · COSENTYX · Enbrel · FORTEO · KRYSTEXXA · Ozempic · PREVNAR 20 · RAYOS · REXULTI · SAPHNELO · SKYRIZI · TRADJENTA · Trintellix · VIMOVO · VRAYLAR · XELJANZ · XIFAXAN · Xembify
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (97%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a rheumatology specialist in Rockaway?
Compare rheumatologists in the Rockaway area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists within 10 mi
92
Per 100K population
18.0
County median income
$134,929
Nearest hospital
SAINT CLARE'S HOSPITAL/ DENVILLE CAMPUS
4.7 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Flowers is a mixed practice specialist, with above-average Medicare volume (top 23% in NJ), with low-engagement industry engagement, with 18 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Flowers experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Flowers performed 43,000 certolizumab injection (cimzia) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Flowers receive payments from pharmaceutical companies?
Yes. Dr. Flowers received a total of $548 from 15 companies across 34 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Flowers's costs compare to other rheumatologists in Rockaway?
Dr. Flowers's average Medicare payment per service is $6. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Flowers) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →